Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
Real-time Quote. Real-time Cboe BZX - 10/23 09:41:12 am
105.165 USD   +5.93%
09:05aALEXION PHARMACEUTICALS : Board Approves $1 Billion Buyback
DJ
07:10aALEXION PHARMACEUTICALS : 3Q Net Profit Rises; Raises Full-Year Guidance
DJ
06:47aALEXION : 3Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Alexion Pharmaceuticals : Raises Outlook After Strong First Quarter

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2019 | 07:13am EDT

By Bowdeya Tweh

Alexion Pharmaceuticals Inc. (ALXN) raised its profit and sales outlook this year after posting stronger-than-expected first-quarter results, bolstered by growth in Soliris and newer treatments like Ultomiris.

Profit in the latest period more than doubled to $587.9 million, or $2.61 a share.

Excluding one-time items, Alexion earned $2.39 a share. Analysts polled by FactSet expected $2.21 a share.

Revenue rose 23%, to $1.14 billion, as analysts expected $1.13 billion.

For the full year Alexion expects per-share earnings of $6.76 to $7.96, or $9.25 to $9.45 as adjusted, on revenue of $4.68 billion to $4.75 billion. The company had expected per-share earnings of $6.14 to $7.26, or $9.10 to $9.30 as adjusted, on $4.63 billion to $4.7 billion in revenue.

Write to Bowdeya Tweh at bowdeya.tweh@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
09:05aALEXION PHARMACEUTICALS : Board Approves $1 Billion Buyback
DJ
07:59aALEXION PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..
AQ
07:15aALEXION PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
07:10aALEXION PHARMACEUTICALS : 3Q Net Profit Rises; Raises Full-Year Guidance
DJ
06:47aALEXION : 3Q Earnings Snapshot
AQ
06:32aALEXION PHARMACEUTICALS : Reports Third Quarter 2019 Results
BU
10/21ALEXION PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
10/21ALEXION PHARMACEUTICALS : Receives FDA Approval for ULTOMIRIS for Atypical Hemol..
AQ
10/18ALEXION PHARMACEUTICALS : Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz..
BU
10/18WeissLaw LLP Investigates Achillion Pharmaceuticals, Inc.
PR
More news
Financials (USD)
Sales 2019 4 845 M
EBIT 2019 2 720 M
Net income 2019 1 941 M
Finance 2019 532 M
Yield 2019 -
P/E ratio 2019 11,7x
P/E ratio 2020 11,0x
EV / Sales2019 4,48x
EV / Sales2020 3,65x
Capitalization 22 261 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 152,04  $
Last Close Price 99,28  $
Spread / Highest target 85,3%
Spread / Average Target 53,1%
Spread / Lowest Target 5,76%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS3.46%22 261
CSL LIMITED35.42%78 131
BIOGEN INC.-6.33%51 990
SAMSUNG BIOLOGICS CO LTD--.--%19 419
GRIFOLS18.65%18 234
WUXI BIOLOGICS CAYMAN INC--.--%13 051